IP Verse

Tablet Formulations Of Neratinib Maleate - EP2498756

The patent EP2498756 was granted to Wyeth on Feb 15, 2023. The application was originally filed on Nov 2, 2010 under application number EP10779339A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2498756

WYETH
Application Number
EP10779339A
Filing Date
Nov 2, 2010
Status
Patent Maintained As Amended
Jan 13, 2023
Grant Date
Feb 15, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEMay 21, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6002008
DESCRIPTIONUS6288082
DESCRIPTIONUS6297258
DESCRIPTIONUS6384051
DESCRIPTIONUS7399865
INTERNATIONAL-SEARCH-REPORTWO2005037287
INTERNATIONAL-SEARCH-REPORTWO2006116514
INTERNATIONAL-SEARCH-REPORTWO2007130438
INTERNATIONAL-SEARCH-REPORTWO2008089087
INTERNATIONAL-SEARCH-REPORTWO2008093878
INTERNATIONAL-SEARCH-REPORTWO2011002857
OPPOSITIONWO2005028443
OPPOSITIONWO2005037287
OPPOSITIONWO2006116514
OPPOSITIONWO2008089087
OPPOSITIONWO2011002857

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BOYCE, J. CLIN. INVEST., (1992), vol. 90, page 1622
DESCRIPTION- BRIDGES, A. J., EMERGING DRUGS, (1998), vol. 3, page 279
DESCRIPTION- DILIP PARIKH, Handbook of Pharmaceutical Granulation Technology, MARCEL DEKKER, (1997), vol. 25, pages 338 - 368
DESCRIPTION- FOLKMAN, J., NATURE MEDICINE, (1995), vol. 1, page 27
DESCRIPTION- J.J. JASPER, "The Surface Tension of Pure Liquid Compounds", J. PHYS. CHEM. REF. DATA, (1972), vol. 1, no. 4, page 859
DESCRIPTION- MATTSSON, E., TRENDS CARDIOVAS. MED., (1995), vol. 5, page 200
DESCRIPTION- RAINES, E. W., BIOESSAYS, (1996), vol. 18, page 271
DESCRIPTION- SHAW, TRENDS PHARMACOL. SCI., (1995), vol. 16, page 401
DESCRIPTION- SHAWVER, L. K., DRUG DISCOVERY TODAY, (1997), vol. 2, page 50
DESCRIPTION- "Surface Free-Energy Components of Liquids and Low Energy Solids and Contact Angles", COLLOID INTERF. SCI, (1989), vol. 127, pages 189 - 204
DESCRIPTION- "Surface Tension of Pure Liquids and Binary Liquid Mixture", Landolt Bornstein, New Series, SPRINGER VERLAG, (1998), vol. IV/16
DESCRIPTION- TRAXLER, P. M., EXP. OPIN. THER. PATENTS, (1998), vol. 8, page 1599
DESCRIPTION- W.R. GOOD, "A Comparison of Contact Angle Interpretations", J. COLLOID INTERF. SCI., (1973), vol. 44, page 63
OPPOSITION- A. REID et al., "Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu", Eur. J. Cancer, (20070000), vol. 43, doi:10.1016/j.ejca.2006.11.007, pages 481 - 489
OPPOSITION- Avicel® PH-101, https://www.sigmaaldrich.com/catalog
OPPOSITION- BEDARD PHILIPPE L et al., "Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer", CURRENT CANCER DRUG TARGETS MAR 2009 LNKD- PUBMED:19275756, (20090300), vol. 9, no. 2, pages 148 - 162
OPPOSITION- "Chapters 25, 27 and 28", Aulton ME, Churchill Livingstone, (20010000), pages 364-378, 397 - 448, ISBN 9780443055171
OPPOSITION- "Chapters 25, 27 and 28", Aulton ME, Churchill Livingstone, (20010000), pages 364-378, 397 - 448, ISBN 9780443055171, XP055720472
OPPOSITION- ClinicalTrials.gov. entry for clinical trial of D16 (NCT00397046)
OPPOSITION- Ehab Hamed, Derek Moe, Raj Khankari, John Hontz, "4. Binders and Solvents", Ehab Hamed, Derek Moe, Raj Khankari, John Hontz, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology, Second Edition, Taylor & Francis, (20050000), vol. 198, pages 109 - 128, ISBN 9780824726478
OPPOSITION- Ehab Hamed, Derek Moe, Raj Khankari, John Hontz, "4. Binders and Solvents", Ehab Hamed, Derek Moe, Raj Khankari, John Hontz, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology, Second Edition, Taylor & Francis, (20050000), vol. 198, pages 109 - 128, ISBN 9780824726478, XP055720708
OPPOSITION- Expert Declaration of Prof. PhD. Patrick J. Sinko
OPPOSITION- "Film coating of oral and solid dosage forms + Tablet Manufacture", James Swarbrick, ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY Third Ed., (20070101), vol. 3 and 6, pages Cover-V, 1729-1747, 3653 - 3672, ISBN 978-0-8493-9399-0
OPPOSITION- "Film coating of oral and solid dosage forms + Tablet Manufacture", James Swarbrick, ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY Third Ed., (20070101), vol. 3 and 6, pages Cover-V, 1729-1747, 3653 - 3672, ISBN 978-0-8493-9399-0, XP055720699
OPPOSITION- Handbook of Pharmaceutical Manufacturing Formulations, Compressed Solid Products, Vol.1, 2nd Ed., Niazi, 2009
OPPOSITION- HEYMACH J V et al., "Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer", CLINICAL CANCER RESEARCH, US, (20060715), vol. 12, no. 14, ISSN 1078-0432, pages 4441 s - 4445s
OPPOSITION- Ito et al. Jpn. J. Clin. Oncol. 2012, 42(4), 278-286
OPPOSITION- Kadam et al. Asian J. Pharm. Clin. Res. 2009, 2, 39-43
OPPOSITION- Kibbe AH, "Povidone", Kibbe AH, Raymond C Rowe, Paul J Sheskey, Marian E Quinn, Handbook Of Pharmaceutical Excipients 6th Edition, (20090000), pages 581 - 585, ISBN 978 0 85369 792 3
OPPOSITION- Kibbe AH, "Povidone", Kibbe AH, Raymond C Rowe, Paul J Sheskey, Marian E Quinn, Handbook Of Pharmaceutical Excipients 6th Edition, (20090000), pages 581 - 585, ISBN 978 0 85369 792 3, XP055720711
OPPOSITION- Planinsek, O. ; Pisek, R. ; Trojak, A. ; Srcic, S., "The utilization of surface free-energy parameters for the selection of a suitable binder in fluidized bed granulation", INTERNATIONAL JOURNAL OF PHARMACEUTICS,, ELSEVIER, NL, (20001010), vol. 207, no. 1-2, ISSN 0378-5173, pages 77 - 88
OPPOSITION- Planinsek, O. ; Pisek, R. ; Trojak, A. ; Srcic, S., "The utilization of surface free-energy parameters for the selection of a suitable binder in fluidized bed granulation", INTERNATIONAL JOURNAL OF PHARMACEUTICS,, ELSEVIER, NL, (20001010), vol. 207, no. 1-2, ISSN 0378-5173, pages 77 - 88, XP027380133
OPPOSITION- WIDAKOWICH C et al., "HER-2 positive breast cancer: What else beyond trastuzumab- based therapy?", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, NL, (20080601), vol. 8, no. 5, pages 488 - 496
OPPOSITION- WISSNER ALLAN et al., "The development of HKI-272 and related compounds for the treatment of cancer", ARCHIV DER PHARMAZIE AUG 2008 LNKD- PUBMED:18493974, (20080800), vol. 341, no. 8, pages 465 - 47 7
OPPOSITION- WISSNER ALLAN et al., "The development of HKI-272 and related compounds for the treatment of cancer", ARCHIV DER PHARMAZIE AUG 2008 LNKD- PUBMED:18493974, (20080800), vol. 341, no. 8, pages 465 - 47 7, XP002591683
OPPOSITION- A. REID et al., "Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu", Eur. J. Cancer, (20070000), vol. 43, doi:10.1016/j.ejca.2006.11.007, pages 481 - 489, XP005868776
OPPOSITION- HEYMACH J V et al., "Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer", CLINICAL CANCER RESEARCH, US, (20060715), vol. 12, no. 14, ISSN 1078-0432, pages 4441 s - 4445s, XP002553862
OPPOSITION- BEDARD PHILIPPE L et al., "Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer", CURRENT CANCER DRUG TARGETS MAR 2009 LNKD- PUBMED:19275756, (20090300), vol. 9, no. 2, pages 148 - 162, XP009136078
OPPOSITION- WIDAKOWICH C et al., "HER-2 positive breast cancer: What else beyond trastuzumab- based therapy?", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, NL, (20080601), vol. 8, no. 5, pages 488 - 496, XP008114462

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents